• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

6,787
2,308
2,237
1,865
1,727

COUNTRY

1,033
871
272
254
210

CATEGORIES

  • 858
  • 186
  • 681
  • 1,129
  • 399
  • 270
  • 255
  • 66
  • 382
  • 728
  • 1,341
  • 1,356
  • 626
  • 884
  • 1,708
  • 2,691
  • 507
  • 734
  • 0
  • 93

PRICE

7,470
12,515
20,278
26,510

PUBLISHED

2,927
3,792
8,317
26,510

PRODUCT TYPE

21,635
2,901
872
827
164
44
21
21
18
6
1

Pharmaceuticals

The pharmaceutical industry has been for decades one of the most profitable worldwide. Serious challenges, such as the expiry of long-term lucrative patents (Lipitor, to mention just one) and the cuts in healthcare and R&D in many countries worldwide, can pose a challenge to the growth of the industry. Which drug can save the life of the pharmaceutical industry? Highly differentiated strategies: this is what companies should focus on now if they want to stay competitive. Do you want to know more?

You can get a detailed picture of the market and refine your marketing, brand, and sales strategies with the reliable, up-to-date business information provided by the extensive range of reports, books and subscriptions listed under Research and Markets’ Pharmaceuticals category. They cover markets, companies (big Pharma, mid-sized specialty pharmaceutical companies, generic manufacturers, and small firms), technologies, e-healthcare, pharmaeconomics, drug discovery, and drug delivery.

The product coverage is huge. It includes OTC drugs as well disorder and goal-specific products related to respiration, oncology, vitamins, cardio, analgesics, central nervous system, generics, immune disorders, and women’s health. Show Less
Read more

PRODUCT TITLE
DAINIPPON SUMITOMO PHARMA - Expectation From BBI-608 To Achieve FY2017 MTP Target Looks Unachievable! DAINIPPON SUMITOMO PHARMA - Expectation From BBI-608 To Achieve FY2017 MTP Target Looks Unachievable! - Product Thumbnail Image

DAINIPPON SUMITOMO PHARMA - Expectation From BBI-608 To Achieve FY2017 MTP Target Looks Unachievable!

Dainippon Sumitomo (DSP) is one of those Japanese pharma companies which has changed its orbit through the successful US launch of Latuda (Lurasidone, dopamine-2, serotonin-2 and serotonin-7 receptors...

January 2014
FROM
TAKEDA - Challenges Ahead for its New European President TAKEDA - Challenges Ahead for its New European President - Product Thumbnail Image

TAKEDA - Challenges Ahead for its New European President

Post Nycomed and Millenium acquisition, the new leadership of non-Japanese CEO/President Mr Weber will transform Takeda into a truly global Japanese company in the coming years It is however important...

January 2014
FROM

Merger and Acquisition (M&A) Trends in the Global Pharmaceutical and Biotechnology Industry

This research service analyzes merger and acquisition trends in the global pharmaceutical and biotechnology industry, along with specific merger and acquisition deals in this industry Analysis is based...

January 2014
FROM
Global Pharmaceutical & Biotechnology Outlook 2014: Major US and EU Global Pharmaceutical & Biotechnology Outlook 2014: Major US and EU - Product Thumbnail Image Special Offer Sale Banner

Global Pharmaceutical & Biotechnology Outlook 2014: Major US and EU

Strategy Diversification Divested: Productivity measurements, divestment of non-core assets resulting in healthy cash position This will accelerate the next wave of targeted acquisition In recent years...

January 2014
FROM
Pharmaceuticals in Australia: ISIC 2423 Pharmaceuticals in Australia: ISIC 2423 - Product Thumbnail Image

Pharmaceuticals in Australia: ISIC 2423

The Industrial reports provide a 360 degree view of an industry. The Industrial market report offers a comprehensive guide to the size and shape of the Pharmaceuticals market at a national level. It...

January 2014
FROM

Cambodia and Laos Pharmaceuticals and Healthcare Report Q1 2014

BMI View: Cambodia will continue to underperform other pharmaceutical markets in the Asia Pacific region, given its low health and pharmaceutical expenditure as well as the rampant corruption in the...

January 2014

Norway Pharmaceuticals and Healthcare Report Q1 2014

BMI View: While Norway's pharmaceutical market is small, BMI believes the country's high public expenditure on health, stringent regulatory climate (recognised by the US and the EU) and stable and transparent...

January 2014

Iran Pharmaceuticals and Healthcare Report Q1 2014

BMI View: Iran's pharmaceutical market is developing. Access to basic healthcare is widespread, reaching about 90% of the rural population and almost the entire urban population. The use of locally...

January 2014

Czech Republic Pharmaceuticals and Healthcare Report Q1 2014

BMI View: The Czech healthcare system is facing severe challenges as it struggles to contain budget deficits. At the same time, demand for the latest pharmaceuticals and access to healthcare services...

January 2014

United Arab Emirates Pharmaceuticals and Healthcare Report Q1 2014

BMI View: The UAE has a well-developed healthcare and pharmaceuticals market, with a growing private sector encouraging investment and increasing demand for innovative drugs, particularly those that...

January 2014

South Africa Pharmaceuticals and Healthcare Report Q1 2014

BMI View: A deteriorating macroeconomic outlook for the country in 2013 and 2014 will see the consumption of medicines and healthcare services slow in the short-term. Additionally, ongoing depreciation...

January 2014

Ghana Pharmaceuticals and Healthcare Report Q1 2014

BMI View: Late 2013 saw Ghana mark the 10th anniversary of the creation of its national health insurance scheme (NHIS). While there are considerable variations in the claims made as to the number of...

January 2014

Romania Pharmaceuticals and Healthcare Report Q1 2014

BMI View: We forecast sluggish growth in Romania's pharmaceutical market over the short term due to greater private contributions to the cost of healthcare and stubbornly high unemployment levels. This...

January 2014

Greece Pharmaceuticals and Healthcare Report Q1 2014

BMI View: We have further downgraded our outlook on Greece's healthcare market this quarter. Further cuts to spending have led to a worsening of the healthcare crisis, with millions of people unable...

January 2014

India Pharmaceuticals and Healthcare Report Q1 2014

BMI View: Due to its large population and substantial unmet medical needs, India represents a market with strong commercial opportunities for pharmaceutical firms. However, we highlight that the government...

January 2014
Mesenchymal Stem Cells in Cancer Therapy Mesenchymal Stem Cells in Cancer Therapy - Product Thumbnail Image

Mesenchymal Stem Cells in Cancer Therapy

With the thorough understanding of stem cell biology and the advent of targeted therapeutics for cancer, stem cell-based therapeutic strategies are being increasingly explored for the treatment of various...

January 2014

European Pharmaceutical Directory 2014

The market potential of the European biotechnology and pharmaceutical sector is enormous and business opportunities abound However, unraveling the maze of who's who, and who does what is a daunting...

January 2014
FROM

International Directory of Generics Companies 2014

This powerful directory is your connection to the key decision-makers in the Generics pharmaceutical industry worldwide The International Directory of Generics Companies is the most comprehensive and...

January 2014
FROM

Asian Pharmaceutical Directory 2014

Keep up-to-date with the Asian Pharmaceutical Industry and discover thousands of new business leads with this the top source of information on 10,000 pharmaceutical and biotechnology companies throughout...

January 2014
FROM

USA Pharmaceutical Directory 2014

The USA Pharmaceutical Directory is one of the most comprehensive and accurate Directory of companies and executives in the USA pharmaceutical industry that have ever been published It contains more...

January 2014
FROM
Loading Indicator

Our Clients

Our clients' logos